Silo Pharma (SILO) Projected to Post Quarterly Earnings on Friday

Silo Pharma (NASDAQ:SILO) is expected to be posting its results after the market closes on Friday, May 8th. Analysts expect Silo Pharma to post earnings of ($0.32) per share and revenue of $0.0180 million for the quarter.

Silo Pharma (NASDAQ:SILO) last released its quarterly earnings results on Friday, March 27th. The company reported $0.03 EPS for the quarter. The company had revenue of $0.02 million for the quarter. Silo Pharma had a negative return on equity of 83.53% and a negative net margin of 5,870.83%.

Silo Pharma Stock Down 2.2%

SILO opened at $0.45 on Wednesday. The firm has a market cap of $7.34 million, a price-to-earnings ratio of -0.84 and a beta of 0.65. Silo Pharma has a 52 week low of $0.22 and a 52 week high of $1.13. The business’s 50 day moving average is $0.40 and its two-hundred day moving average is $0.41.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silo Pharma in a research report on Friday, April 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SILO. DRW Securities LLC acquired a new position in shares of Silo Pharma in the fourth quarter valued at approximately $113,000. Virtu Financial LLC acquired a new position in shares of Silo Pharma in the third quarter valued at approximately $74,000. Finally, Geode Capital Management LLC increased its holdings in shares of Silo Pharma by 134.6% in the fourth quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock valued at $32,000 after purchasing an additional 53,309 shares during the period. Institutional investors and hedge funds own 5.58% of the company’s stock.

About Silo Pharma

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.